Paper Details

  1. Home
  2. Paper Details

Effects of Teriflunomide on B Cell Subsets in MuSK-Induced Experimental Autoimmune Myasthenia Gravis and Multiple Sclerosis.

Author: HajtovicSabastian, KurtuncuMurat, LazaridisKonstantinos, TurkogluRecai, TuzunErdem, TzartosJohn, UlusoyCanan, YilmazVuslat

Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study suggests that teriflunomide, a drug approved for multiple sclerosis (MS), could be a potential treatment for MuSK-associated myasthenia gravis (MG). Teriflunomide treatment ameliorated MuSK-autoimmunity in mice and reduced effector B cell ratios in both mice and MS patients.
Paper Details　
Original Abstract of the Article :
Antigen-specific immune responses are crucially involved in both multiple sclerosis (MS) and myasthenia gravis (MG). Teriflunomide is an immunomodulatory agent approved for treatment of MS through inhibition of lymphocyte proliferation. MG associated with muscle-specific tyrosine kinase (MuSK) antib...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/08820139.2020.1785491

データ提供：米国国立医学図書館（NLM）

Teriflunomide: A New Oasis for Myasthenia Gravis and Multiple Sclerosis

Myasthenia gravis and multiple sclerosis (MS) are autoimmune disorders that can feel like a relentless desert storm, attacking the body's own immune system. The researchers in this study explored the potential of teriflunomide, an immunomodulatory drug, to tame the storm and bring about a more peaceful equilibrium.

Teriflunomide: A Potential Relief for Autoimmune Disorders

The study found that teriflunomide effectively reduced the severity of experimental autoimmune myasthenia gravis (EAMG) in mice and also showed a similar pattern in MS patients. This finding is like discovering a hidden oasis in the desert, offering a potential new treatment for these debilitating autoimmune diseases.

A Promising Path for Immunomodulatory Treatment

Teriflunomide, like a calming desert wind, appears to work by inhibiting the overactive immune response, bringing about a more balanced state. However, further research is needed to fully understand the long-term impact of this treatment on patients with myasthenia gravis and MS.

Dr.Camel's Conclusion

This study offers a glimmer of hope for individuals with myasthenia gravis and MS, suggesting a potential new path for treatment. While more research is needed, teriflunomide shows promise as a potential oasis in the desert of autoimmune disorders.

Date :
  1. Date Completed 2021-12-15
  2. Date Revised 2021-12-15
Further Info :

Pubmed ID

32597289

DOI: Digital Object Identifier

10.1080/08820139.2020.1785491

Related Literature

Article Analysis
・Effects of teriflunomide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.